The SYOLIGO project is part of the IPCEI Med4Cure approved by the European Commission on May 28, 2024, and addresses the development and sustainable manufacturing of RNA-based therapies for rare diseases. Sylentis participates as IPCEI direct partner.

Vision

Sylentis, with the SYOLIGO project, seeks to promote new therapeutic approaches with RNA oligonucleotides aimed at rare diseases and to become a European benchmark in the sustainable production of oligonucleotides.

learn more

Mission

SYOLIGO will strengthen the technology base and provide the essential facilities to support the sustainable growth of Sylentis as a leading pharmaceutical company in the EU, specializing in the development and production of RNA-based products.

learn more

Vision

Sylentis, with the SYOLIGO project, seeks to promote new therapeutic approaches with RNA oligonucleotides aimed at rare diseases and to become a European benchmark in the sustainable production of oligonucleotides.

learn more

Mission

SYOLIGO will strengthen the technology base and enable the facilities necessary to sustainably grow Sylentis as a leading pharmaceutical industry in the EU for the development and manufacture of RNA nucleic acid-based products.

learn more

Objectives

First Industrial Deployment (FID)

  • Start-up of a new sustainable oligonucleotide production plant in Spain.
  • Reduction of the PMI sustainability parameter of the oligonucleotide manufacturing process.
  • Introduction of innovative oligonucleotide production processes.

Research and development (R&D)

  • Develop RNA-based therapies for the most efficient targeted treatment of rare diseases.
  • Actively collaborate with IPCEI partners.